Avails Medical Achieves Major Milestone with First Commercial Deal in History

Avails Medical Marks a New Era in Healthcare with First Commercial Agreement

Avails Medical, Inc., based in Menlo Park, California, has officially announced a groundbreaking milestone in its history by signing its inaugural commercial agreement. This deal involves the prestigious eQUANT™ System, a pioneering technology aimed at revolutionizing antibiotic susceptibility testing (AST). The company has partnered with a renowned academic medical center that serves as the flagship hospital for a network of six hospitals.

The eQUANT™ System is designed to enhance the management of sepsis patients by delivering rapid and accurate testing results, significantly improving patient outcomes. This cutting-edge technology is set to enable healthcare providers to receive timely data, thereby allowing for better treatment decisions for critically ill patients.

Transforming Antibiotic Susceptibility Testing

One of the key advantages of the eQUANT™ System is its ability to provide results within approximately 70 minutes. Traditional AST methods usually take 24 hours or longer, meaning that delays in testing can hinder the timely administration of effective treatment to patients suffering from sepsis. The eQUANT™ System addresses this gap effectively, allowing for faster targeted therapy in a streamlined and efficient manner.

The technology features a compact design with a user-friendly interface that seamlessly integrates into existing laboratory workflows. This innovative aspect not only enhances laboratory efficiency but also supports widespread adoption across various hospital settings, thus playing a crucial role in the global fight against antibiotic resistance.

Oren Knopfmacher, Co-Founder and CEO of Avails Medical, expressed pride in the achievement, stating, "I am so proud of the Avails team for this accomplishment and installing the first eQUANT™ Systems at such a prestigious institution. It truly is a testament to how novel and impactful the eQUANT™ System is in speeding up the time to actionable results for the sickest patients." This sentiment reflects the team's dedication to making substantial contributions to healthcare.

Leadership Appointment

In conjunction with the announcement of the commercial agreement, Avails Medical has also appointed Jason Kniebel as the Vice President of Sales. Kniebel brings over two decades of experience in business development within the life sciences and diagnostics fields. His previous role as Vice President of Sales at T2 Biosystems included overseeing various operations, further enhancing his capability to steer Avails Medical toward sustainable growth.

Kniebel expressed enthusiasm about his new role, stating, "I am honored to join the incredible team at Avails Medical, which is committed to improving patient outcomes and fighting antimicrobial resistance through innovative, affordable, and rapid testing solutions. I look forward to leading the effort to drive sustainable business growth now and into the future."

About Avails Medical, Inc.

Founded to combat one of the most serious global health challenges—antibiotic resistance—Avails Medical, Inc. harnesses all-electrical technology to reduce the time necessary for generating reliable antibiotic susceptibility data. Their proprietary electronic biosensor technology eliminates the need for time-consuming manual culturing, which enhances the speed and accuracy of pathogen quantification and susceptibility testing directly from human specimens.

For additional details about Avails Medical and the eQUANT™ System, visit www.availsmedical.com.

This landmark agreement not only signifies a key achievement for Avails Medical but also represents a crucial step towards addressing the pressing issue of antibiotic resistance in healthcare, marking a significant moment in the company's journey toward creating better health outcomes for patients worldwide.